The purpose of this presentation is to provide to you the results of an assignment given to me by Dr. Holland, namely, to review the matter of immunomodulatory therapy in children, in particular in children with uveitis. In an effort to discharge this responsibility given to me, I reviewed the literature relevant to pediatric immunomodulatory therapy for non-malignant, non-ocular disease in an effort to determine, to the extent possible, information regarding the safety of such therapy for children with non-malignant disease. Additionally, I have reviewed the literature on immunomodulatory therapy in children with ocular inflammatory disease. The central question I have tried to address is that of, Êwhat is the evidence supporting the efficacy and safety for immunomodulatory therapy for steroid-resistant or steroiddependent ocular inflammatory disease?ˆ
A computer-based (MEDLINE), search of the database from the National Library of Medicine, Bethesda, Maryland, of the literature from 1970 to 2000 on the use of immunomodulatory therapy in non-ocular, non-malignant disease in children, and in the use of immunomodulatory therapy in ocular inflammatory disease in children was conducted. An attempt at analyzing reported side effects, toxicity, and complications was made. Additionally, an analysis of our experience in Dr. Foster’s practice in pediatric immunomodulatory therapy over the past 25 years was performed.
The non-ocular, non-malignant disorders for which immunomodulatory therapy was prescribed which I reviewed included solid organ and bone marrow transplants, rheumatic disorders, vasculitis disorders, including childhood Granulomatosis with Polyangiitis (formerly called Wegener’s), polyarteritis nodosa, and Adamantiades-Beh¨etÿs disease, dermatologic disorders, including childhood pemphigus vulgaris and psoriasis, asthma and nephrotic syndrome. Three-thousand, one-hundred and eight publications were reviewed. It became immediately apparent that a variety of impediments to clarity of analysis existed for many of the nonocular, non-malignant disorders for which immunomodulatory therapy might be prescribed. For example, 1,074 publications on solid organ and bone marrow transplantation were reviewed. But multiple immunomodulatory therapy agents, combined into Êrecipesˆ were employed for each patient in each of those publications. Additionally, underlying illness which led to the transplant also confounded the picture. And finally, concurrent use of chronic systemic steroid confused matters.1-10 Clear data to emerge from this analysis, however, include: major medication induced nephrotoxicity and neurotoxicity was common in children treated with either cyclosporin or with tacrolimus (FK506) for prevention of solid organ transplant or bone marrow transplant rejection or in treatment of nephrosis;1,9 infection was relatively common in children treated concomitantly with systemic steroid and an immunosuppressant;5mycophenolate mofetil at 600 mg/m2+ bid is subtherapeutic (more acute renal allograft rejections) and more toxic than are therapeutically effective doses of azathioprine.5
Of the childhood rheumatic diseases assayed (juvenile idiopathic arthritis, systemic lupus erythematosus, relapsing polychondritis, localized scleroderma and polymyositis), the best data emerge from the juvenile idiopathic arthritis (JIA) literature. Two hundred and thirty-three publications on the matter of immunomodulatory therapy for JIA were reviewed. Methotrexate was the immunomodulatory agent used most commonly, by far.11-14 However, publications on the use of cyclosporin, azathioprine, and chlorambucil were also useful.
Ruperto and associates11 studied 132 children with JIA treated with methotrexate, with no reported clinically significant drug-induced complications. Woo and colleagues12 reported that one of the 27 children with JIA treated with 15-20 mg/m2 methotrexate required drug discontinuation secondary to rising liver enzymes after the patient contracted hepatitis A.
Giannini and associates studied 127 children with juvenile idiopathic arthritis, 86 of whom were treated with methotrexate (Êlow doseˆ or Êvery low doseˆ), comparing both efficacy and side effects with an additional 41 children treated with placebo in a double-blind placebo-controlled trial. Only three children treated with methotrexate discontinued therapy because of side effects, and none had significant toxicity.
The side effects included gastrointestinal upset and oral mucosal aphthous ulceration. All side effects were graded as either mild or moderate in severity, except for 2 episodes of stomach pain graded as severe in a patient receiving placebo.
Laxer concludes, in his summary on the matter14 that methotrexate therapy for JIA is the mainstay of treatment of that disease because of both its efficacy and its safety, pointing out that liver toxicity is very uncommon, as are osteopathy, embryopathy and malignancy, with any even remote association with the latter being controversial and unclear.
Weiss, Wallace, and Sherry, in their 1998 publication, reported on 7 children with steroid-dependent uveitis and cataract and glaucoma, whom they treated with methotrexate, in a dose to 1mg/kg/week given subcutaneously.15 Uveitis was controlled in six of the seven patients, allowing steroid to be discontinued or at least dramatically reduced. The time to response was 1-4 months. Three of seven patients had rising serum aminotransferase levels during the appropriate monitoring, necessitating dose reduction of the methotrexate; no patient required discontinuation of medication because of complications. Weiss and associates conclude that early use of methotrexate may allow for complete suppression of JIAassociated uveitis and reduce the cumulative exposure to corticosteroids in refractory cases.
We had previously reported similar findings and recommendations in a 1992 article, and in an expanded series on 160 patients with uveitis treated with methotrexate;16,17 ÂÂforty of these patients were children. Our data confirmed the safety profile of this drug, and further emphasized its utility in control of uveitis in patients with steroid-dependent uveitis. However, the group of children in whom the highest proportion failed to completely respond to methotrexate were those with juvenile idiopathic arthritis; in this group of patients, 75% responded to this drug, while 25% required the addition of a second agent or a switch to an alternative agent.17
Good, easily analyzable data could not be obtained from the publications relating to Adamantiades-
Beh¨etÿs disease, Granulomatosis with Polyangiitis (formerly called Wegener’s), polyarteritis nodosa, Churg-Strauss syndrome, Goodpastureÿs syndrome, Crohnÿs disease, pemphigus vulgaris, eczema, psoriasis, epidermolysis bullosa acquisita, asthma, or autoimmune hepatitis.18-26However, excellent, easily usable data emerged from an analysis of the literature on nephrotic syndrome (see below). Six-hundred and seventy-four publications on the matter of nephrotic syndrome were reviewed. The immunomodulatory agents typically employed in the care of children with frequently relapsing, steroid-dependent nephrotic syndrome included cyclosporin, cyclophosphamide, and chlorambucil. The cyclophosphamide regimens involved in the studies included 5mg/kg/day by mouth, or 75mg/m2/day by mouth for up to 52 weeks. The chlorambucil doses employed in the trials analyzed included 0.2mg/kg/day and 0.3mg/kg/day. The cyclosporin dose employed was 6mg/kg/day.
Analysis of adverse effects in a meta-analysis by Durkan and associates disclosed the
following.27 Chlorambucil at 0.3mg/kg/day is highly toxic and frequently associated with unacceptable levels of leukopenia. Cyclosporin at 6mg/kg/day is frequently associated with nephropathy, hypertension, hirsutism, and gum hypertrophy; lesser doses are ineffective for inducing remission in nephrotic syndrome. Therefore, cyclosporin is believed by the authors to be inappropriate for this indication.
The meta-analysis showed that the relative risk for nephrotic syndrome relapse was 0.44 following cyclophosphamide therapy, so that the risk of relapse is reduced from 100% to 40%, i.e., 60 fewer children relapse for each 100 treated. For every 100 treated, one will develop an infection and four will develop cystitis. Therefore, a risk/benefit analysis is highly appropriate before any child is committed to cyclophosphamide therapy. For example, children who relapse only once during the first six months after an initial course of prednisone therapy have only a 10% risk of becoming a frequent relapser, i.e., 10 of 100. Cyclophosphamide therapy would reduce this risk by 60%, and so only 6 of 100 such children would benefit from cyclophosphamide therapy, while the number suffering adverse effects would remain unchanged. Therefore, the risk/benefit ratio would be acceptable only for children with frequently relapsing syndrome. A similar exercise in estimating a risk/benefit ratio in considering steroid-sparing immunomodulatory therapy for children with uveitis is clearly appropriate.
An estimate of the risk/benefit ratio in children with juvenile idiopathic arthritis with dependency on steroid versus moving on to low dose once weekly methotrexate therapy is straightforward. The data on safety and efficacy of methotrexate therapy for this indication are clear, and clearly indicate that the risk/benefit ratio calculation for children whose arthritis is steroid-dependent or treatment-resistant favors moving along to methotrexate immunomodulatory therapy. Similarly, the same estimate of risk versus benefit can be done for children with JIA-associated iridocyclitis. Just as in the case of children with nephrotic syndrome, not every child with JIA-associated iridocyclitis is destined to have a chronic, or recurrent, or conventional-treatment-resistant course. But good data exist regarding prognosticators for identifying patients whose JIA-associated uveitis is more likely than not to be chronic, recurrent, or Êstubbornˆ. Kanski and others for example, have suggested that those JIA patients who develop uveitis prior to the onset of arthritis have a worse prognosis than those in whom arthritis develops first.28
Wolfe and associates attempted to analyze visual prognostic factors in 51 patients with JIA-associated uveitis by dividing their patients into mild or advanced uveitis subgroups. Those who had posterior synechiae and active inflammation at the time of presentation to the ophthalmologist had a worse longterm outcome than did those who had no active inflammation at first evaluation.29 Edelsten and associates30 recently reported on their study of 163 patients with JIA-associated uveitis, in an attempt to evaluate baseline risk factors predictive of severity and chronicity of the uveitis. Like Wolfe, these researchers found that complications and a generally poor outcome were significantly more common in those patients who had uveitis at the time of their initial screening visit with the ophthalmologist. Further, they confirmed the observations of others that the more severe the uveitis was at presentation, the more likely vision-damaging complications would ensue throughout the course of the patientÿs disease.
Our work on this matter,31 based on our analysis of 43 patients with JIA-associated uveitis identified those patients referred to our Service as being comprised of 93% with chronic uveitis, 5% with recurrent uveitis, and 2% with an acute monophasic disease course. The mean overall duration of the uveitis was 146 months, with females suffering from a significantly longer duration of active disease than did males. The female sex, longer duration of uveitis, younger age at uveitis onset, and longer delay between onset of uveitis and presentation to a uveitis subspecialist were associated significantly with visual acuity impairment. The same factors, along with dependence on corticosteroids (lack of treatment with systemic antiinflammatory medication aside from steroids) were correlated strongly with a final visual acuity outcome of less than 20/40. We concluded that earlier case identification and referral to a uveitis specialist trained and prepared to engage in immunomodulatory therapy of such patients had the best chance of minimizing the likelihood of visual impairment in patients with JIA-associated uveitis. Therefore, the 12-year-old boy who is HLA-B27 negative, ANA negative, with oligoarticular juvenile idiopathic arthritis who has 2 or 3 mild episodes of anterior uveitis clearly should not be advanced to methotrexate immunomodulatory therapy for care of his eye disease. On the other hand, such a patient with severe uveitis at the outset, which is still requiring topical with or without regional injection or systemic steroid 6 months after the first visit to the ophthalmologist should seriously be considered for advancement to methotrexate. Similarly, the 2-year-old female who is ANA positive with oligoarticular arthritis, found on initial screening examination to have significantly impaired visual acuity in one eye, with posterior synechiae in both eyes and a significant cataract in one eye should almost certainly be seriously considered for methotrexate therapy almost immediately.
The meta-analysis study by Latta and associates32 analyzed 38 studies involving 1504 children and 1573 courses of cytotoxic drug therapy. The regimens involved in those 38 studies included cyclophosphamide at a dose of 2-5mg/kg/day or chlorambucil at 0.1-0.2mg/kg/day.
Leukopenia was common, but generally as a desired Êside effectˆ of effective alkylating therapy. Infection developed in 1.5% of patients on cyclophosphamide, but in 6.3% of patients receiving chlorambucil. Additionally, 0.2% of patients on cyclophosphamide developed a malignancy, while 0.6% of patients on chlorambucil therapy did so. Three percent of patients on chlorambucil therapy developed a seizure disorder, and 2.2% of patients on cyclophosphamide developed cystitis.
The authors conclude that the margin between effective treatment and a dose toxic to the patient is too narrow for chlorambucil, and that therefore cyclophosphamide is the preferred therapy for steroiddependent, frequently relapsing nephrotic syndrome.
Additional matters of significant interest to us within ophthalmology confronted by the need to decide about alkylating therapy are gonadal toxicity and secondary malignancy. Guesry concludes that the margin between effective treatment and a dose toxic to the gonads was smaller with chlorambucil than with cyclophosphamide.33 He estimates that 17mg/kg chlorambucil cumulative dose with concurrent steroid use is safe for the gonads of males, while 200mg/kg of cyclophosphamide could be used safely. The gonadal toxicity of cytotoxic therapy was less severe in females than in males in his study, and pregnancies had been reported after cumulative doses of up to 525mg/kg of cyclophosphamide and after up to 28mg/kg for chlorambucil.
Nephrotic syndrome has been associated with lymphoma, and 2 children with nephrotic syndrome without cytotoxic therapy have had leukemia. Therefore, attributing malignancy in nephrotic syndrome treated with immunomodulatory therapy is complicated. Fourteen of 1504 children reported in the meta-analysis of Latta et al32 developed a malignancy, and some of the malignancies were ones that one would not traditionally associate with being a consequence of alkylating therapy.
Additionally, in some of the cases, the doses of alkylating agent had been quite low, calling into question the relationship between the alkylating therapy and the malignancy. But it seems clear that a relationship can exist, and, further, that the higher the cumulative dose, the more likely a leukemia may develop. Chlorambucil, in particular, has been associated with leukemia. But at the doses and durations typically employed in children with ocular inflammatory disease, this appears not to be a significant issue.
Latta et al recommend that the criteria for treating children with nephrotic syndrome with cytotoxic therapy should include a frequently relapsing nature of the nephrotic syndrome, the development of steroid toxicity, such as cataract and growth failure and Cushingoid status, and/or the development of psychological complications from the use of steroid.32Cyclophosphamide is preferred over chlorambucil, with oral cyclophosphamide at a dose of 2-3mg/kg/day, keeping the white count above 3000 cell/m3, and employing alternative day steroid concomitantly. Latta suggests aiming for less than 300mg/kg cumulative dose in males.32
Pulse intravenous cyclophosphamide therapy may, in fact, be the best approach of all in this setting of frequently relapsing nephrotic syndrome. Gulati et al reported on this strategy of treating 51 children with steroid-dependent, frequently relapsing nephrotic syndrome.34The mean age of the children was 4 years, and the dose employed was 500mg/m2/month for six months, with a 5-year follow up. The authors concluded that this is a safe and effective way of administering alkylating therapy, comparable in efficacy to oral daily cyclophosphamide, with 40% less cumulative dose, and therefore fewer side effects. The side effects included nausea and vomiting at the time of infusion (5%), alopecia (8%), leukopenia (4%), pneumonitis (2%), and infection (2%). No patient discontinued therapy due to a side effect. Mok et al similarly extol the virtues of pulse intravenous cyclophosphamide in their care of children with diffuse proliferative lupus glomerulonephritis.35 They studied 55 patients, 22 receiving intravenous cyclophosphamide and 33 receiving oral cyclophosphamide. The patients receiving IV pulse cyclophosphamide never developed cystitis, whereas 5% of the patients receiving oral cyclophosphamide did. Half the menstruating females on oral cyclophosphamide developed oligomenorrhea, whereas only 25% of those receiving IV pulse cyclophosphamide did.
Finally, Lehman and Onel additionally speak to the matter of intermittent intravenous pulse cyclophosphamide in the care of children with systemic lupus erythematosus nephritis.36Sixteen children with systemic lupus erythematosus associated glomerulonephritis were treated with intravenous pulse cyclophosphamide for 36 months. The regimen involved a dosage of 500-750mg/m2 monthly for six months, followed by that same dose every 3 months for the succeeding 30 months. Side effects included nausea during the infusion (this was typically controllable and necessitated no change in therapy) alopecia (none to the extent of complete baldness), and leukopenia (an inescapable and, frankly, essential Êside effectˆ from cyclophosphamide therapy, without which the therapeutic effect will never be achieved). No child withdrew from therapy during the entire course of treatment, no instances of cystitis were encountered, no female reaching pubescence developed amenorrhea, and no patient has developed a malignancy.
Rosenbaum37 applied this approach, but at reduced dose, for 11 adults with steroid-resistant uveitis, reporting that five of the 11 benefited from this approach. We, on the other hand, have
been very impressed at both the safety and the efficacy of intravenous pulse cyclophosphamide therapy in the care of patients whose uveitis has failed to adequately respond not only to systemic and regional steroid therapy, but has also failed to remit with more conventional, orally administered immunomodulatory agents, such as methotrexate, cyclosporin, azathioprine and mycophenolate mofetil.38
Abundant reliable published evidence exists in the worldÿs peer-reviewed literature attesting to the safety of several immunomodulatory agents for treating both ocular and systemic non-malignant inflammatory disease. Some agents are clearly safer than others. For example, methotrexate has an extraordinary safety record in the care of patients with such disorders. Cyclosporin is more toxic in children at therapeutic doses. Mycophenolate mofetil, an immunomodulatory agent quite useful in the care of adults with ocular inflammatory disease39,40 is more toxic to children than is azathioprine or methotrexate.3Cyclophosphamide, particularly given in the intravenous pulse mode, is clearly superior, at least from a safety standpoint, to daily oral cyclophosphamide and to daily oral chlorambucil.
Click here to listen to
Uveitis and Steroid-Sparing Therapy
Presented by C. Stephen Foster, MD, FACS, FACR
Audio-Digest Ophthalmology Volume 56, Issue 15
Click on the Register link
In the email you receive, click on the change password link.
Change your password